ERBB2 and triple-negative breast carcinoma: While chemotherapy remains the backbone of treatment for triple-negative breast cancer (TNBC), endocrine and human epidermal growth factor receptor 2 (HER2) targeted therapies provide the gold standard for hormone receptor-positive (HR+) and HER2-positive (HER2+) tumors, respectively (3, 4).